2021-2026年腫瘤領域的合作與授權協議

Oncology Collaboration and Licensing Deals 2021-2026

出版日期: 2026年10月01日 | 出版商:

Current Partnering | 英文 1400+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

利用 2,955 項現有合作與許可協議的信息，了解腫瘤領域的合作趨勢。

《2021-2026 年腫瘤合作與許可協議》提供了有關 2,955 項與腫瘤資產、技術和開發計劃相關的合作交易的全面資訊。

腫瘤學仍然是製藥和生物技術領域合作最活躍的領域之一，各公司利用合作關係和許可，在快速發展的治療領域中獲得新的標靶、療法、開發項目和商業性機會。

本報告將這些廣泛的交易趨勢匯總到一個資源中，使用戶能夠了解哪些公司正在合作，哪些腫瘤學機會正在吸引關注，交易的結構是什麼，披露了哪些財務條款，以及交易如何因適應症、技術和開發階段而異。

這份報告不只是簡單地列出了交易清單；它結合了全面的市場交易分析和財務基準分析、主要交易商的信息、詳細的交易記錄，以及在有公開合約文件的情況下對其進行訪問。

本報告為負責人腫瘤合作的業務發展、許可、交易來源和評估、公司策略、研發策略、競爭情報和法律團隊提供可操作的資訊和基準數據。

了解腫瘤領域合作的趨勢

本報告分析了2021年至2026年腫瘤領域的交易情況，內容包括：

腫瘤領域合作的年度趨勢
按交易類型分類的交易趨勢
產業部門
合作關係發展階段
技術類型
適應症
腫瘤領域最活躍的交易商
根據已揭露的交易金額，主要交易金額
腫瘤領域合作活動的趨勢
這使用戶能夠確定他們的活動集中在哪些方面，並了解哪些公司、技術、開發階段和治療領域正在吸引合作興趣。
腫瘤領域交易財務條款的基準分析
腫瘤領域的財務條款會因資產、開發階段、技術、競爭格局、授予的權利以及交易的整體結構而有很大差異。

本報告對已揭露的財務狀況進行了詳細分析，包括以下項目：

交易總額
預付款
里程碑付款
版稅率
透過分析這些基準背後的具體交易，使用者可以更全面地了解所揭露條款的經濟狀況。
這為內部基準測試、機會評估、交易準備和談判提供了一個現實的基準。
財務基準只有在結合類似交易的結構和情況進行解讀時才最有用，而不僅僅是作為平均值來解讀。本報告提供了建立這種背景所需的基礎交易資訊。
確定腫瘤領域的關鍵交易商和未來夥伴。
本報告列出了在腫瘤領域合作活動最活躍的公司，並提供了詳細的交易歷史記錄，以便用戶可以調查這些公司過去的活動。

這有助於用戶識別以下內容：

積極尋求腫瘤領域機會的公司
有潛力的許可和合作研究夥伴
我們曾多次與相關癌症適應症領域的組織合作。
積極參與相關開發階段的公司
對特定目標、技術或療法感興趣的交易商。
競爭對手正在推廣相關的外部創新策略
對於尋求腫瘤治療資產和技術合作夥伴的公司而言，過去的交易歷史可以提供寶貴的見解，了解哪些組織對類似的機會表現出了興趣。
我們將比較針對每種癌症適應症和標靶的合作活動。
腫瘤學涵蓋了非常廣泛的腫瘤適應症、生物標的和治療方法，每一種都有其獨特的科學、臨床和商業性趨勢。
本報告按治療適應症和治療標靶分析合作關係，使用戶能夠專注於與特定項目或策略關注事項最相關的交易，而不是僅對整體腫瘤領域進行基準分析。
透過結合對技術和發展階段的分析，用戶可以發現更多有意義的類似交易和潛在的未來合作夥伴關係。
了解腫瘤學領域合約的結構
本報告涵蓋合作研究、授權、開發、調查和其他合作交易。

根據交易詳情和資訊披露，用戶可以調查以下方面：

授予和保留的權利
研發職責
授權權
獨家版權
區域權利
智慧財產
發展和監管義務
負責生產和供應
商業化權利
金錢補償
里程碑和版稅
管治
合約期限和終止條款
這些例子在考慮腫瘤學合作的合適框架時可能很有用。
從實際合約文件中學習
本報告提供了部分腫瘤相關交易的基礎合約文件（如有）。

這些合約提供的資訊遠比簡單的標題公告所能展現的要詳細得多，使用戶能夠檢驗公司如何記錄諸如以下事項：

權利範圍
發展義務
智慧財產
獨家版權
財務狀況
里程碑觸發條件
特許權使用費規定
商業化權利
合約終止及其他談判事項
對於準備和談判腫瘤學領域合作研究和許可協議的團隊來說，獲取實際的合約措辭可以提供關於類似交易實際結構方式的寶貴見解。
綜合腫瘤學交易目錄
本報告包含 2,955 項與腫瘤學相關的合作與許可協議的綜合目錄，為識別相關先例提供了廣泛的資訊來源。

可以使用以下條件搜尋交易記錄：

公司
技術類型
治療適應症或標靶
合約揭露狀態
每筆交易都與其底層交易記錄相關聯，從而可以存取詳細的交易資訊和相關的合約文件（如有）。
誰該使用這份報告？
業務拓展與授權團隊
識別類似的腫瘤相關交易、有前景的合作夥伴以及相關的交易結構。
研究與評估團隊
我們將確定哪些公司正在積極探索相關適應症、技術、標靶和開發階段的腫瘤學機會。
尋求合作夥伴的生技公司
找出對類似腫瘤學資產或技術表現出明確興趣的組織。
企業策略與研發策略團隊
我們將了解我們的競爭對手和潛在的未來合作夥伴如何透過外部創新來建立其腫瘤產品組合。
競爭情報與市場分析團隊
按公司、適應症、目標、開發階段和技術追蹤合作趨勢，以了解不斷變化的策略重點。
法律及交易團隊
我們將仔細審查公開的合約和以往的合約結構，以幫助您準備和談判交易。
經營團隊與投資組合策略團隊
我們將了解整個腫瘤學領域中資本、合作夥伴關係和外部創新活動的集中地點。
我們將全市場範圍的腫瘤學資訊轉化為公司特有的洞察。
符合資格的客戶除了收到報告外，還將收到 Current Partnering 提供的客製化合作夥伴簡報。
本次簡報將說明有關腫瘤交易的基礎信息，並根據您的特定資產、技術、適應症、目標或合作目標量身定做。
如有需要，我們可以提供相關的類似交易、潛在的未來合作關係、競爭對手的活動、發展階段分析、交易結構、財務基準、忠誠度分析、合約見解以及其他專門為您情況選擇的情報。
請索取樣本或聯絡 Current Partnering 討論本報告的內容以及我們是否可以為貴公司提供客製化分析。

The report brings this extensive deal activity together in one resource, enabling users to understand who is partnering, which oncology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in oncology partnering.

Understand the oncology partnering landscape

The report analyzes oncology dealmaking from 2021 to 2026, including:

Trends in oncology partnering by year
Deal activity by deal type
Industry sector
Stage of development at the time of partnering
Technology type
Therapeutic indication
Most active oncology dealmakers
Leading deals by disclosed value
How oncology partnering activity is evolving
This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
Benchmark oncology deal financials
Financial terms in oncology can vary significantly according to the asset, development stage, technology, competitive landscape, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

Headline deal values
Upfront payments
Milestone payments
Royalty rates
Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading oncology dealmakers and prospective partners
The report identifies the most active companies in oncology partnering and provides extensive transaction histories that enable users to investigate their previous activity.

This can help users identify:

Companies actively seeking oncology opportunities
Prospective licensing and collaboration partners
Organizations repeatedly partnering in relevant cancer indications
Companies active at relevant stages of development
Dealmakers demonstrating interest in particular targets, technologies or therapeutic modalities
Competitors pursuing related external innovation strategies
For companies seeking to partner an oncology asset or technology, previous transaction activity can provide valuable evidence of which organizations have demonstrated an appetite for comparable opportunities.
Compare partnering activity across oncology indications and targets
Oncology encompasses a very broad range of cancer indications, biological targets and therapeutic approaches, each with different scientific, clinical and commercial dynamics.
The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad oncology benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Understand how oncology agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

Rights granted and retained
Research and development responsibilities
Licensing rights
Exclusivity
Geographic rights
Intellectual property
Development and regulatory obligations
Manufacturing and supply responsibilities
Commercialization rights
Financial consideration
Milestones and royalties
Governance
Term and termination provisions
These real-world examples provide useful reference points when considering the appropriate structure for an oncology partnership.
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected oncology transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

Scope of rights
Development obligations
Intellectual property
Exclusivity
Financial terms
Milestone triggers
Royalty provisions
Commercialization rights
Termination and other negotiated provisions
For teams preparing or negotiating an oncology collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
Comprehensive oncology deal directory
The report includes a comprehensive directory of 2,955 oncology collaboration and licensing deals, providing an extensive resource for identifying relevant precedent transactions.

Deals can be reviewed by:

Company
Technology type
Therapeutic indication or target
Contract availability
Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
Who should use this report?
Business Development and Licensing teams
Identify comparable oncology transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking oncology opportunities across relevant indications, technologies, targets and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable oncology assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building oncology portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Senior Management and Portfolio Strategy teams
Understand where capital, partnering attention and external innovation activity are being concentrated across the oncology landscape.
Turn market-wide oncology intelligence into company-specific insight
For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
The briefing applies the underlying oncology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.